These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19133231)

  • 1. Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway.
    Fu P; Jiang X; Arcasoy MO
    Biochem Biophys Res Commun; 2009 Feb; 379(3):696-701. PubMed ID: 19133231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
    Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
    Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
    Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S
    Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin enhancement of rat pancreatic tumor cell proliferation requires the activation of ERK and JNK signals.
    Bose C; Udupa KB
    Am J Physiol Cell Physiol; 2008 Aug; 295(2):C394-405. PubMed ID: 18550701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogen-activated protein kinase plays an essential role in the erythropoietin-dependent proliferation of CTLL-2 cells.
    Sakamoto H; Kitamura T; Yoshimura A
    J Biol Chem; 2000 Nov; 275(46):35857-62. PubMed ID: 10960479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.
    Hardee ME; Cao Y; Fu P; Jiang X; Zhao Y; Rabbani ZN; Vujaskovic Z; Dewhirst MW; Arcasoy MO
    PLoS One; 2007 Jun; 2(6):e549. PubMed ID: 17579721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin drives breast cancer progression by activation of its receptor EPOR.
    Chan KK; Matchett KB; Coulter JA; Yuen HF; McCrudden CM; Zhang SD; Irwin GW; Davidson MA; Rülicke T; Schober S; Hengst L; Jaekel H; Platt-Higgins A; Rudland PS; Mills KI; Maxwell P; El-Tanani M; Lappin TR
    Oncotarget; 2017 Jun; 8(24):38251-38263. PubMed ID: 28418910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells.
    Paragh G; Kumar SM; Rakosy Z; Choi SC; Xu X; Acs G
    Am J Pathol; 2009 Apr; 174(4):1504-14. PubMed ID: 19264915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and does not require tyrosine docking sites in the EPO receptor.
    Chen J; Jacobs-Helber SM; Barber DL; Sawyer ST
    Exp Cell Res; 2004 Aug; 298(1):155-66. PubMed ID: 15242770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2.
    Aguilar C; Aguilar C; Lopez-Marure R; Jiménez-Sánchez A; Rocha-Zavaleta L
    Mol Med Rep; 2014 May; 9(5):1895-902. PubMed ID: 24626629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor.
    Miura Y; Miura O; Ihle JN; Aoki N
    J Biol Chem; 1994 Nov; 269(47):29962-9. PubMed ID: 7961995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of a constitutively active erythropoietin receptor in primary hematopoietic progenitors abrogates erythropoietin dependence and enhances erythroid colony-forming unit, erythroid burst-forming unit, and granulocyte/macrophage progenitor growth.
    Pharr PN; Hankins D; Hofbauer A; Lodish HF; Longmore GD
    Proc Natl Acad Sci U S A; 1993 Feb; 90(3):938-42. PubMed ID: 7679218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i )protein beta gamma-subunit-initiated pathway.
    Guillard C; Chrétien S; Pelus AS; Porteu F; Muller O; Mayeux P; Duprez V
    J Biol Chem; 2003 Mar; 278(13):11050-6. PubMed ID: 12538595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No erythropoietin-induced growth is observed in non-small cell lung cancer cells.
    Frille A; Leithner K; Olschewski A; Olschewski H; Wohlkönig C; Hrzenjak A
    Int J Oncol; 2018 Feb; 52(2):518-526. PubMed ID: 29345289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia.
    Lester RD; Jo M; Campana WM; Gonias SL
    J Biol Chem; 2005 Nov; 280(47):39273-7. PubMed ID: 16207704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of the erythropoietin receptor in RAMA 37 breast cancer cells alters cell growth and sensitivity to tamoxifen.
    Ilkovičová L; Trošt N; Szentpéteriová E; Solár P; Komel R; Debeljak N
    Int J Oncol; 2017 Aug; 51(2):737-746. PubMed ID: 28714517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor.
    Miura O; Miura Y; Nakamura N; Quelle FW; Witthuhn BA; Ihle JN; Aoki N
    Blood; 1994 Dec; 84(12):4135-41. PubMed ID: 7527668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
    Våtsveen TK; Sponaas AM; Tian E; Zhang Q; Misund K; Sundan A; Børset M; Waage A; Brede G
    J Hematol Oncol; 2016 Aug; 9(1):75. PubMed ID: 27581518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation.
    Arcasoy MO; Harris KW; Forget BG
    Exp Hematol; 1999 Jan; 27(1):63-74. PubMed ID: 9923445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.